Ovid Therapeutics enters ROCK2 inhibitor collaboration with Graviton; invests $10M for exclusive CNS rights

Ovid Therapeutics Inc.

Ovid pays $10M upfront in Graviton Series A preferred stock for exclusive license to GV101 and other ROCK2 inhibitors.
Royalties on net sales range from mid-teens to high-teens; no milestone payments are required.
Initial focus: cerebral cavernous malformations and seizure disorders; GV101 is in Phase 1.
Graviton conducts development through Phase 2; Ovid handles post-Phase 2 development and commercialization worldwide except China, Hong Kong, Macau, Taiwan.
Ovid CEO Dr. Jeremy Levin will join Graviton's Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.